Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    OpGen

    MCap

    USD15m

    Last close

    USD1.78

    ▲ 0.18 (11.13%)

    Substrate AI

    MCap

    EUR11m

    Last close

    EUR0.10

    ▲ 0.01 (11.11%)

    IRLAB Therapeutics

    MCap

    SEK679m

    Last close

    SEK13.10

    ▲ 1.00 (8.26%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

BerGenBio (NO: BGBIO)

Last close As at 29/10/2024

6.12

▲ −0.38 (−5.95%)

Market capitalisation

NOK532m

Edison Investment Research is terminating coverage on BerGenBio. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Flash note

BerGenBio — No surprises as bemcentinib strategy progresses

Healthcare | Flash note

BerGenBio — Focusing in on 1L NSCLC and COVID-19

Healthcare | edison tv

BerGenBio – executive interview

Healthcare | Update

BerGenBio — Checking its course
Visit Website

Sector

Healthcare

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (47.4) (45.2) (72.4)
Relative (40.1) (43.6) (71.5)
52 week high/low NOK21.7/NOK6.0

Financials

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune-evasive cancers and COVID-19. It focuses on AXL inhibitors bemcentinib (small molecule) and tilvestamab (mAb).

Y/E Dec Revenue (NOKm) EBITDA (NOKm) PBT (NOKm) EPS (öre) P/E (x) P/CF (x)
2020A 0.6 (260.4) (257.0) (343.07) N/A N/A
2021A 0.8 (313.1) (309.4) (351.72) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

Flash note

Healthcare

BerGenBio — Focusing in on 1L NSCLC and COVID-19

edison tv

Healthcare

BerGenBio – executive interview

Healthcare

Flash note

BerGenBio — No surprises as bemcentinib strategy progresses

Update

Healthcare

BerGenBio — Checking its course

Flash note

Healthcare

BerGenBio — Martin Olin succeeds Richard Godfrey as CEO

Update

Healthcare

BerGenBio — Advancing towards pivotal studies

Update

Healthcare

BerGenBio — FDA grants fast track designation

Update

Healthcare

BerGenBio — Bemcentinib preliminary data in COVID-19

Update

Healthcare

BerGenBio — AXLeration of data catalysts in 2021

Update

Healthcare

BerGenBio — Progressing towards key inflection points

Thematics

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free